DK0666751T3 - Mutanter af hepatitis A-virus, stamme HM-175, til anvendelse som hepatitis A-vacciner - Google Patents
Mutanter af hepatitis A-virus, stamme HM-175, til anvendelse som hepatitis A-vaccinerInfo
- Publication number
- DK0666751T3 DK0666751T3 DK93921524T DK93921524T DK0666751T3 DK 0666751 T3 DK0666751 T3 DK 0666751T3 DK 93921524 T DK93921524 T DK 93921524T DK 93921524 T DK93921524 T DK 93921524T DK 0666751 T3 DK0666751 T3 DK 0666751T3
- Authority
- DK
- Denmark
- Prior art keywords
- hepatitis
- vaccines
- strain
- hav
- virus mutants
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32432—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94733892A | 1992-09-18 | 1992-09-18 | |
PCT/US1993/008610 WO1994006446A1 (en) | 1992-09-18 | 1993-09-17 | Hepatitis a virus vaccines |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0666751T3 true DK0666751T3 (da) | 2001-11-12 |
Family
ID=25485989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK93921524T DK0666751T3 (da) | 1992-09-18 | 1993-09-17 | Mutanter af hepatitis A-virus, stamme HM-175, til anvendelse som hepatitis A-vacciner |
Country Status (14)
Country | Link |
---|---|
US (4) | US6180110B1 (ja) |
EP (1) | EP0666751B1 (ja) |
JP (1) | JP3523646B2 (ja) |
AT (1) | ATE205536T1 (ja) |
AU (1) | AU687012B2 (ja) |
CA (1) | CA2144317C (ja) |
DE (1) | DE69330758T2 (ja) |
DK (1) | DK0666751T3 (ja) |
ES (1) | ES2164074T3 (ja) |
HK (1) | HK1013667A1 (ja) |
NZ (1) | NZ256278A (ja) |
PT (1) | PT666751E (ja) |
SG (1) | SG73999A1 (ja) |
WO (1) | WO1994006446A1 (ja) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HRP950097A2 (en) | 1994-03-08 | 1997-06-30 | Merck & Co Inc | Hepatitis a virus culture process |
CN1053590C (zh) * | 1998-10-19 | 2000-06-21 | 卫生部长春生物制品研究所 | 冻干甲型肝炎减毒活疫苗及其保护剂 |
US6368602B1 (en) * | 2000-06-16 | 2002-04-09 | Hadasit Medical Research Services And Development Ltd | Mucosal immunization against hepatitis A virus (HAV) through rectal administration of HAV vaccine |
GB0304799D0 (en) | 2003-03-03 | 2003-04-09 | Glaxosmithkline Biolog Sa | Novel method |
US20050220734A1 (en) * | 2004-04-02 | 2005-10-06 | Allergan, Inc. | Therapy for melanin related afflictions |
WO2006007603A2 (en) * | 2004-07-13 | 2006-01-19 | Gen-Probe Incorporated | Compositions and methods for detection of hepatitis a virus nucleic acid |
US20100055670A1 (en) * | 2005-06-28 | 2010-03-04 | The Government of the US, Represented by the Secretary, Dept. of Health and Human Services | Growth of wild-type hepatitis a virus in cell culture |
WO2007134250A2 (en) * | 2006-05-12 | 2007-11-22 | Goldengate Software, Inc. | Method for forming homogeneous from heterogeneous data |
US9907746B2 (en) | 2009-07-06 | 2018-03-06 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
CA2767392C (en) | 2009-07-06 | 2017-03-14 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
CA2840079C (en) | 2010-07-06 | 2018-07-03 | Variation Biotechnologies Inc. | Compositions and methods for treating influenza |
CN102174477B (zh) * | 2010-12-28 | 2012-11-21 | 深圳康泰生物制品股份有限公司 | 甲型肝炎病毒株sh及其二倍体细胞适应方法 |
WO2012097346A1 (en) | 2011-01-13 | 2012-07-19 | Variation Biotechnologies, Inc. | Compositions and methods for treating viral infections |
US20140328876A1 (en) | 2011-11-18 | 2014-11-06 | Variation Biotechnologies Inc. | Synthetic derivatives of mpl and uses thereof |
EP2802353A4 (en) | 2012-01-12 | 2015-12-02 | Variation Biotechnologies Inc | COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS |
US20150079077A1 (en) | 2012-01-27 | 2015-03-19 | Variation Biotechnologies, Inc. | Methods and compositions for therapeutic agents |
KR102277089B1 (ko) | 2019-12-19 | 2021-07-14 | 에스케이바이오사이언스(주) | A형 간염 바이러스의 제조방법 및 상기의 방법에 따라 제조된 a형 간염 바이러스 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2398504A1 (fr) | 1977-07-29 | 1979-02-23 | Tours Inst Virologie | Culture de virus de l'hepatite a, in vitro. application a la production d'un antigene reactif, d'immunserums specifiques et de vaccins contre l'hepatite a |
US4894228A (en) * | 1982-04-07 | 1990-01-16 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine against hepatitis A virus |
US4636469A (en) | 1982-04-07 | 1987-01-13 | The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Isolation of hepatitis A virus strain HM-175 |
US4620978A (en) | 1982-04-07 | 1986-11-04 | The United States Of America As Represented By The Department Of Health And Human Services | Hepatitis A virus purified and triply cloned |
US4532215A (en) | 1982-04-07 | 1985-07-30 | The United States Of America As Represented By The Department Of Health And Human Services | Isolation of hepatitis A virus strain HM-175 |
US5516630A (en) | 1983-09-30 | 1996-05-14 | The United States Of America As Represented By The Department Of Health And Human Services | Methods of detecting hepatitis A virus |
US4783407A (en) * | 1985-09-30 | 1988-11-08 | Merck & Co., Inc. | Growth of hepatitus A virus in vero cells |
GB8800100D0 (en) | 1988-01-05 | 1988-02-10 | Almond J W | Attenuated viruses |
DE542949T1 (de) * | 1991-05-08 | 1993-09-02 | Schweiz. Serum- & Impfinstitut Bern, Bern, Ch | Hepatitis a virusstamm, verfahren zur isolierung eines hepatitis a virusstammes und vakzine hepatitis a. |
-
1993
- 1993-09-17 CA CA002144317A patent/CA2144317C/en not_active Expired - Lifetime
- 1993-09-17 ES ES93921524T patent/ES2164074T3/es not_active Expired - Lifetime
- 1993-09-17 WO PCT/US1993/008610 patent/WO1994006446A1/en active IP Right Grant
- 1993-09-17 JP JP50822594A patent/JP3523646B2/ja not_active Expired - Fee Related
- 1993-09-17 DK DK93921524T patent/DK0666751T3/da active
- 1993-09-17 PT PT93921524T patent/PT666751E/pt unknown
- 1993-09-17 AU AU48585/93A patent/AU687012B2/en not_active Ceased
- 1993-09-17 SG SG1996011170A patent/SG73999A1/en unknown
- 1993-09-17 EP EP93921524A patent/EP0666751B1/en not_active Expired - Lifetime
- 1993-09-17 NZ NZ256278A patent/NZ256278A/en not_active IP Right Cessation
- 1993-09-17 US US08/397,232 patent/US6180110B1/en not_active Expired - Lifetime
- 1993-09-17 AT AT93921524T patent/ATE205536T1/de active IP Right Revival
- 1993-09-17 DE DE69330758T patent/DE69330758T2/de not_active Expired - Lifetime
-
1995
- 1995-06-07 US US08/475,886 patent/US6113912A/en not_active Expired - Lifetime
-
1998
- 1998-12-23 HK HK98115009A patent/HK1013667A1/xx not_active IP Right Cessation
-
2000
- 2000-08-31 US US09/653,499 patent/US6423318B1/en not_active Expired - Fee Related
-
2002
- 2002-04-29 US US10/135,988 patent/US6680060B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JP3523646B2 (ja) | 2004-04-26 |
WO1994006446A1 (en) | 1994-03-31 |
AU687012B2 (en) | 1998-02-19 |
CA2144317A1 (en) | 1994-03-31 |
PT666751E (pt) | 2002-01-30 |
SG73999A1 (en) | 2000-07-18 |
EP0666751A4 (en) | 1996-04-24 |
US6180110B1 (en) | 2001-01-30 |
CA2144317C (en) | 2004-08-03 |
ATE205536T1 (de) | 2001-09-15 |
US6423318B1 (en) | 2002-07-23 |
ES2164074T3 (es) | 2002-02-16 |
DE69330758D1 (de) | 2001-10-18 |
US20020176869A1 (en) | 2002-11-28 |
EP0666751B1 (en) | 2001-09-12 |
EP0666751A1 (en) | 1995-08-16 |
NZ256278A (en) | 1996-11-26 |
US6680060B2 (en) | 2004-01-20 |
JPH08504094A (ja) | 1996-05-07 |
US6113912A (en) | 2000-09-05 |
DE69330758T2 (de) | 2002-07-04 |
HK1013667A1 (en) | 1999-09-03 |
AU4858593A (en) | 1994-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0666751T3 (da) | Mutanter af hepatitis A-virus, stamme HM-175, til anvendelse som hepatitis A-vacciner | |
Barnett et al. | Further studies on the early protective responses of pigs following immunisation with high potency foot and mouth disease vaccine | |
CZ203195A3 (en) | Method of cultivating a virus of a reproductive and respiratory syndrome of pigs and its use in vaccines | |
ES2176232T3 (es) | Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter. | |
NZ226332A (en) | Vaccine comprising transmissible gastroenteritis virus of swine for preventing canine coronavirus infection in dogs and process for preparation thereof | |
AU7763294A (en) | Live in ovo vaccine | |
US4556556A (en) | Vaccine for the prevention of vesicular stomatitis virus infection | |
NO950483L (no) | Vaksine mot hepatitt-A | |
CN101757619A (zh) | 兽用狂犬病灭活疫苗及其制备方法 | |
Dixon et al. | Inactivation of infectious pancreatic necrosis virus for vaccine use | |
DK365287A (da) | Fremgangsmaade til dyrkning af bordetella pertussis, pertussis toxoid, pertussis vacciner og fremgangsmaade til fremstilling af pertussis vacciner | |
DK0833903T3 (da) | Multivalent vaccine mod bovint coronavirus og fremgangsmåde til behandling af infektioner forårsaget af bovint coronavirus | |
FI86376C (fi) | Foerfarande foer framstaellning av renad och tre gaonger klonad hepatitis-a-virus. | |
Lopez et al. | Immune response to foot-and-mouth disease virus in an experimental murine model II. Basis of persistent antibody reaction | |
DE3853736D1 (de) | Staupevirus-Impfstoff. | |
PT603386E (pt) | Imunizacao parenterica contra rotavirus | |
AR009650A1 (es) | Mycoplasma synoviae atenuado vivo, su uso, un cultivo microbiologico que lo comprende, una vacuna bacteriana atenuada viva para la proteccion de las aves de corral contra la infeccion por mycoplasma synoviae y un metodo para preparar dicha vacuna. | |
HUP9700975A2 (hu) | Élő, legyengített, Pasteurellaceae családba tartozó, RTX-termelő baktériumok | |
ES2066206T3 (es) | Utilizacion de adenilciclasa como vacunas contra bordetella. | |
DK52783D0 (da) | Vaccine indeholdende en ozoninaktiveret mikroorganisme og fremgangsmade til fremstilling af en sadan vaccine | |
CA1193565A (en) | Method of preparing an immunogen of pasteurella multocida | |
DK506979A (da) | Vaccine mod infektioes katte-peritonitis og fremgangsmaade til dens fremstilling | |
NL300073I1 (nl) | Vaccin. | |
RU94031386A (ru) | Вакцина сухая культуральная против вирусного энтерита гусей и способ профилактики и лечения вирусного энтерита гусей | |
Morton | Laboratory and field trials of killed Brucella suis type 4 vaccine in reindeer |